Popular filter options for liver cirrhosis trials
Portal Hypertension Clinical Trials
View 15 Portal Hypertension medical studies.
Procedure
BI 685509 + Empagliflozin for Portal Hypertension
This trial is for adults with liver cirrhosis caused by hepatitis B, hepatitis C, or nonalcoholic steatohepatitis. The study is testing whether BI 685509, taken alone or with empagliflozin, helps people with this condition by checking the pressure in a liver vein.
BI 685509 for Portal Hypertension
This trial is testing whether a medicine called BI 685509 can help people with liver cirrhosis and high blood pressure in the portal vein. People are randomly put into 3 groups, taking BI 685509 or placebo tablets twice a day for 8 months. The study measures the change in blood pressure to see if the treatment is effective.
Phase 3 Liver Cirrhosis Clinical Trials
View 89 phase 3 liver cirrhosis medical studies.
Statin
Simvastatin for Liver Cirrhosis
This trial will test whether simvastatin can lower the risk of hepatic decompensation in people with compensated cirrhosis. It will also explore how changes in genes effect the safety and effectiveness of using statins and how the use of statins affects quality of life.
Bile Acid Sequestrant
Linerixibat for Cholestasis
This trial is testing the safety and tolerability of the drug linerixibat in people with a condition called cholestatic pruritus, who have participated in other clinical trials for the same drug. All participants will receive linerixibat during the study, which is expected to last until the drug can be made available for general use. The total duration of the study will vary depending on when each participant joins and the availability of the drug in their country.
Liver Cirrhosis Clinical Trials With No Placebo
View 89 liver cirrhosis medical studies that do not have a placebo group.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Contrast Enhanced Ultrasound for Liver Cirrhosis and Acute Kidney Injury
This trial will test whether contrast-enhanced ultrasound can help diagnose the cause of acute kidney injury in patients with cirrhosis, which would help doctors better treat the condition.
View More Liver Cirrhosis Trials
See another 63 medical studies focused on liver cirrhosis.
Frequently Asked Questions
Introduction to liver cirrhosis
What are the top hospitals conducting liver cirrhosis research?
When it comes to advancing the treatment and understanding of liver cirrhosis, several top hospitals across the United States are leading the way. In Boston, Massachusetts General Hospital stands out with six active clinical trials dedicated to this condition. With a total of 15 liver cirrhosis trials conducted since their first recorded trial in 2000, this renowned institution has been at the forefront of research and innovation in liver health.
Heading west to Rochester, Minnesota, we find another prestigious hospital making significant contributions. The Mayo Clinic currently has five ongoing liver cirrhosis trials and an impressive history of 23 completed studies dating back to their initial trial in 1997. Known for its cutting-edge medical expertise, Mayo Clinic is committed to improving outcomes for patients with liver cirrhosis.
In Pasadena, California Liver Research Institute is making strides in liver health as well. With four active clinical trials focused on liver cirrhosis and a growing portfolio of 11 all-time studies since their first recorded trial in 2015, this institute emphasizes cutting-edge research and personalized care for patients affected by this condition.
Moving further down south to Richmond, Virginia, Hunter Holmes McGuire VA Medical Center is actively involved in addressing liver cirrhosis through four ongoing clinical trials. Since recording their first trial for this condition in 2011, they have built a robust history with a total of 19 completed studies aimed at enhancing diagnosis and treatment options for individuals living with liver cirrhosis.
Lastly but certainly not least important is University of California San Francisco located right within San Francisco itself; here researchers are conducting three rigorous clinical tests towards battling against cases associated with livecirhossis while also contributing significantly towards progress through seven previously held investigations starting from recordationof there venture into such experiments during years as recent as2013.Their location allows them access countless resources support which only furthers advancements made by staff & physicians alike
These distinguished hospitals illustrate how collaborative research efforts and innovative clinical trials are paving the way for improved outcomes in liver cirrhosis management. With each study and trial, these institutions bring us closer to more effective treatments, enhanced quality of life for patients, and ultimately a future where liver cirrhosis can be prevented or treated with greater success.
Which are the best cities for liver cirrhosis clinical trials?
When it comes to liver cirrhosis clinical trials, several cities emerge as prominent hubs for cutting-edge research. Los Angeles, California leads the way with 18 ongoing trials investigating treatments like PF-06865571, Active, and CSG452. Following closely behind is Richmond, Virginia with 17 active studies focusing on belapectin, OCE-205, and Health IT +/- Scheduled Follow Up. Miami, Florida also showcases a strong presence in the field with 16 trials exploring IVA337, PF-06865571, and Cohort C: Rencofilstat 225 mg. Lastly, New york City boasts 14 active trials studying belapectin and PF-06865571 among others. These cities offer individuals affected by liver cirrhosis access to cutting-edge clinical trials that advance our understanding of this complex condition and pave the way for improved treatments in the future.
Which are the top treatments for liver cirrhosis being explored in clinical trials?
The search for effective treatments for liver cirrhosis is ongoing, with several promising options currently being explored in clinical trials. Leading the charge is the Jumpstart Guide, a novel approach that has caught researchers' attention. It is currently involved in one active trial focused on liver cirrhosis and marks its first listing in 2023. Another contender making waves in the field is Hepatology Home Hospital, also engaged in one active liver cirrhosis trial since 2023. Lastly, LPCN 1148 shows potential as a treatment option through its involvement in one active trial and first listing in 2021. These innovative therapies offer hope for patients battling this challenging condition and may pave the way to improved outcomes.
What are the most recent clinical trials for liver cirrhosis?
Exciting advancements in the treatment of liver cirrhosis are emerging through recent clinical trials. One notable trial, named Active, is currently in Phase 2 and offers potential breakthroughs for individuals with this condition. Another study, Arm 1, has progressed to Phase 3 and holds promise as a viable option for those suffering from liver cirrhosis. Additionally, Semaglutide exhibits encouraging results in its Phase 2 trial for this disease. Furthermore, a Phase 3 trial focusing on the combination of lactulose treatment alongside enhanced usual care demonstrates promising outcomes for patients with liver cirrhosis. Lastly, Bemnifosbuvir and Ruzasvir show potential benefits based on their ongoing Phase 2 evaluation. These trials collectively offer hope for improved treatments and better quality of life among individuals battling liver cirrhosis.
(Corrected response)
What liver cirrhosis clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of liver cirrhosis research, offering hope for patients grappling with this complex condition. In November 2021 alone, two important trials were completed: one sponsored by Stanford University focusing on Empagliflozin 10 MG and another led by the University of Michigan investigating Lactulose. Additionally, Georgetown University's Proglumide trial concluded in March 2021. These breakthroughs build upon earlier advancements from a range of sponsors including Beth Israel Deaconess Medical Center, NGM Biopharmaceuticals Inc., Novartis Pharmaceuticals, Hunter Holmes Mcguire Veteran Affairs Medical Center, Bristol-Myers Squibb, and Intercept Pharmaceuticals between 2017 to 2020. This collective effort signifies the commitment of researchers towards unraveling new therapeutic approaches for liver cirrhosis patients.